Cargando…

Differences in response to treatment in children with severe IgA nephropathy according to patient age

Aim: To clarify whether the response to treatment of IgA nephropathy (IgAN) differs depending on patient age, we examined the response to treatment according to age of onset in children with IgAN. Methods: We collected data for 44 children with severe IgAN. The children were retrospectively divided...

Descripción completa

Detalles Bibliográficos
Autores principales: Kawasaki, Yukihiko, Kume, Yohei, Ono, Atsushi, Maeda, Ryo, Go, Hayato
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Fukushima Society of Medical Science 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10480517/
https://www.ncbi.nlm.nih.gov/pubmed/37164762
http://dx.doi.org/10.5387/fms.2022-42
_version_ 1785101804418105344
author Kawasaki, Yukihiko
Kume, Yohei
Ono, Atsushi
Maeda, Ryo
Go, Hayato
author_facet Kawasaki, Yukihiko
Kume, Yohei
Ono, Atsushi
Maeda, Ryo
Go, Hayato
author_sort Kawasaki, Yukihiko
collection PubMed
description Aim: To clarify whether the response to treatment of IgA nephropathy (IgAN) differs depending on patient age, we examined the response to treatment according to age of onset in children with IgAN. Methods: We collected data for 44 children with severe IgAN. The children were retrospectively divided into three groups based on their age at disease onset. Group 1 consisted of 24 children under 11 years old, group 2 consisted of 9 children aged 12 to 13 years, and group 3 consisted of 11 children aged over 14 years old. The clinical features and prognosis were analyzed for each group. Results: The urinary protein excretion and serum IgA values in group 3 were higher than those in groups 1 and 2 at the most recent follow up, and histological findings showed that the MESTCG scores in group 3 were higher than those in group 1. Furthermore, the incidence of patients with persistent nephropathy or renal insufficiency in group 3 was higher than those in groups 1 and 2. Conclusions: Patients aged 14 years and older with IgAN may respond poorly to treatment compared with those younger than 14 years old. Therefore, care must be taken regarding response to treatment and relapse when treating older children.
format Online
Article
Text
id pubmed-10480517
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher The Fukushima Society of Medical Science
record_format MEDLINE/PubMed
spelling pubmed-104805172023-09-07 Differences in response to treatment in children with severe IgA nephropathy according to patient age Kawasaki, Yukihiko Kume, Yohei Ono, Atsushi Maeda, Ryo Go, Hayato Fukushima J Med Sci Original Article Aim: To clarify whether the response to treatment of IgA nephropathy (IgAN) differs depending on patient age, we examined the response to treatment according to age of onset in children with IgAN. Methods: We collected data for 44 children with severe IgAN. The children were retrospectively divided into three groups based on their age at disease onset. Group 1 consisted of 24 children under 11 years old, group 2 consisted of 9 children aged 12 to 13 years, and group 3 consisted of 11 children aged over 14 years old. The clinical features and prognosis were analyzed for each group. Results: The urinary protein excretion and serum IgA values in group 3 were higher than those in groups 1 and 2 at the most recent follow up, and histological findings showed that the MESTCG scores in group 3 were higher than those in group 1. Furthermore, the incidence of patients with persistent nephropathy or renal insufficiency in group 3 was higher than those in groups 1 and 2. Conclusions: Patients aged 14 years and older with IgAN may respond poorly to treatment compared with those younger than 14 years old. Therefore, care must be taken regarding response to treatment and relapse when treating older children. The Fukushima Society of Medical Science 2023-05-11 2023 /pmc/articles/PMC10480517/ /pubmed/37164762 http://dx.doi.org/10.5387/fms.2022-42 Text en © 2023 The Fukushima Society of Medical Science https://creativecommons.org/licenses/by-nc-sa/4.0/This article is licensed under a Creative Commons [Attribution-NonCommercial-ShareAlike 4.0 International] license. https://creativecommons.org/licenses/by-nc-sa/4.0/
spellingShingle Original Article
Kawasaki, Yukihiko
Kume, Yohei
Ono, Atsushi
Maeda, Ryo
Go, Hayato
Differences in response to treatment in children with severe IgA nephropathy according to patient age
title Differences in response to treatment in children with severe IgA nephropathy according to patient age
title_full Differences in response to treatment in children with severe IgA nephropathy according to patient age
title_fullStr Differences in response to treatment in children with severe IgA nephropathy according to patient age
title_full_unstemmed Differences in response to treatment in children with severe IgA nephropathy according to patient age
title_short Differences in response to treatment in children with severe IgA nephropathy according to patient age
title_sort differences in response to treatment in children with severe iga nephropathy according to patient age
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10480517/
https://www.ncbi.nlm.nih.gov/pubmed/37164762
http://dx.doi.org/10.5387/fms.2022-42
work_keys_str_mv AT kawasakiyukihiko differencesinresponsetotreatmentinchildrenwithsevereiganephropathyaccordingtopatientage
AT kumeyohei differencesinresponsetotreatmentinchildrenwithsevereiganephropathyaccordingtopatientage
AT onoatsushi differencesinresponsetotreatmentinchildrenwithsevereiganephropathyaccordingtopatientage
AT maedaryo differencesinresponsetotreatmentinchildrenwithsevereiganephropathyaccordingtopatientage
AT gohayato differencesinresponsetotreatmentinchildrenwithsevereiganephropathyaccordingtopatientage